Annual report pursuant to Section 13 and 15(d)

Recent Developments, Liquidity and Management???s Plans (Details Narrative)

v3.22.1
Recent Developments, Liquidity and Management’s Plans (Details Narrative) - USD ($)
 12 Months Ended
Apr. 16, 2021
Dec. 31, 2021
Dec. 31, 2020
Mar. 23, 2020
Dec. 31, 2019
Goodwill   $ 10,498,539    
Cash and Cash Equivalents, at Carrying Value   555,967 148,284    
Marketable Securities, Current   11,003,071    
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest   29,889,045 9,487,824    
Working Capital   11,625,519      
Stockholders' Equity Attributable to Parent   23,647,174 (5,257,032)   $ (2,332,830)
Retained Earnings (Accumulated Deficit)   78,561,568 48,672,523    
Net Cash Provided by (Used in) Operating Activities   19,516,475 4,663,546    
Net Income (Loss) Attributable to Parent   29,889,045 9,487,824    
Increase (Decrease) in Accounts Payable, Trade   4,268,961 (557,286)    
Stock Option Modification Expenses   $ 15,036,051 $ 2,009,145    
Restricted Stock Units (RSUs) [Member]          
Shares vested        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value        
Contribution Agreement [Member] | Premas Biotech PVT Ltd [Member]          
Amount owed on investments   $ 1,500,000      
Payments to investments   $ 1,200,000      
Merger Agreement [Member]          
Issuance of post reverse stock split 28,553,307        
Exchange ratio percentage 77.05%        
Percentage of common stock 49.68%        
Merger Agreement [Member] | Pre-funded Warrants [Member]          
Warrants to purchase 986,486        
Cystron Biotech LLC [Member] | Membership Interest Purchase Agreement [Member]          
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage       100.00%  
MYMD Pharmaceuticals, Inc., [Member] | Merger Agreement [Member]          
Business acquisition description Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued 28,553,307 post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio. Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD Florida held approximately 77.05% of the Company’s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants to purchase 986,486 shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company’s net cash at closing. Holders of pre-Merger common stock of the Company held approximately 22.95% of the outstanding equity of the Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315 MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of the Merger.        
Akers Biosciences, Inc [Member]          
Goodwill $ 10,498,539        
Pre market capitalization 42,477,346        
Tangible asset $ 31,978,807        
Shares issued for acquistion   8,335,627      
Akers Biosciences, Inc [Member] | Restricted Stock Units (RSUs) [Member]          
Shares vested   263,026      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value   $ 4.94